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Abstract 
We have previously reported that novel vitronectin:growth factor (VN:GF) complexes 
significantly increase re-epithelialization in a porcine deep dermal partial-thickness burn 
model. However, the potential exists to further enhance the healing response through 
combination with an appropriate delivery vehicle which facilitates sustained local release and 
reduced doses of VN:GF complexes. Hyaluronic acid (HA), an abundant constituent of the 
interstitium, is known to function as a reservoir for growth factors and other bioactive species. 
The physicochemical properties of HA confer it with an ability to sustain elevated 
pericellular concentrations of these species. This has been proposed to arise via HA 
prolonging interactions of the bioactive species with cell surface receptors and/or protecting 
them from degradation. In view of this, the potential of HA to facilitate the topical delivery of 
VN:GF complexes was evaluated. Two-dimensional (2D) monolayer cell cultures and 3D de-
epidermised dermis (DED) human skin equivalent (HSE) models were used to test skin cell 
responses to HA and VN:GF complexes. Our 2D studies revealed that VN:GF complexes and 
HA stimulate the proliferation of human fibroblasts but not keratinocytes. Experiments in our 
3D DED-HSE models showed that VN:GF complexes, both alone and in conjunction with 
HA, led to enhanced development of both the proliferative and differentiating layers in the 
DED-HSE models. However, there was no significant difference between the thicknesses of 
the epidermis treated with VN:GF complexes alone and VN:GF complexes together with HA. 
While the addition of HA did not enhance all the cellular responses to VN:GF complexes 
examined, it was not inhibitory, and may confer other advantages related to enhanced 
absorption and transport that could be beneficial in delivery of the VN:GF complexes to 
wounds.  
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1. Introduction 
   Since their discovery late last century, growth factors have been examined for their 
potential as wound therapeutics. Experimental evidence has shown that transforming growth 
factor β (TGF-β) and vascular-endothelial growth factor (VEGF) accelerate the healing of 
wounds in animal models [1, 2]. Platelet-derived growth factor (PDGF) has been shown to 
accelerate the healing of human diabetic foot ulcers [3], and basic fibroblast growth factor 
(bFGF) has been approved as a treatment for wounds in Japan [4]. Several other growth 
factors have exhibited benefits in clinical trials, for example, granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and epidermal growth factor (EGF) [5, 6]. However, in 
every report to date, high doses of these growth factors have been applied to obtain successful 
wound healing results. Significantly, these therapeutic strategies ignore the central 
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coordinating role of the extracellular matrix (ECM) in orchestrating and enhancing the 
cascade of cellular events in the wound healing response [7].  
   Recent studies in our laboratory have found that the binding of the ECM protein vitronectin 
(VN) to insulin-like growth factor (IGF), IGF-binding proteins (IGFBPs) and EGF 
significantly enhanced the proliferation and migration of primary skin keratinocytes [8]. In 
addition, these novel complexes of VN, IGF, IGFBPs and EGF (VN:GF complexes) have 
been found to significantly enhance re-epithelialization in a porcine deep dermal partial-
thickness burn model [9]. In this proof-of-principle study VN:GF complexes were directly 
delivered to burn injury sites in water. Water is potentially a less than ideal excipient and 
topical application using alternative delivery vehicles may further improve the healing 
outcomes, for example, by prolonging the exposure of the complex to the wound bed and/or 
reducing the dose of VN:GF complexes required.  
   Hyaluronic acid (HA) was discovered in bovine vitreous humour by Meyer and Palmer in 
1934 and is an important constituent of all connective tissues in the body [10]. Its 
physicochemical properties complement the activity of small molecules, including diclofenac 
and ibuprofen [11], pilocarpine and tropicamide [12, 13], xylometazoline and vasopressin [14, 
15], taxol and manganese [16, 17], cisplatin [18], doxorubicin [19] and insulin [20]. The 
successful clinical outcomes established with these pharmaceuticals has facilitated 
development of novel delivery techniques, including liposomes [21], anti-bacterial and anti-
inflammatory drugs [22, 23], implantable drugs  and DNA [24].    
   While growth factors have well recognised roles in the wound healing cascade [25], the 
viscoelasticity, hygroscopicity, biocompatibility and immunocompatability of HA confer it 
with a facilitating role that may potentiate or maximize tissue responses to growth factors. 
Hopkinson stated in 1992 that ‘effective repair is dependent on the coordinated activities of 
both regulatory molecules and structural molecules’ [26]. In view of this we examined the 
application of VN:GF complexes in combination with HA to skin cells.  
2. Methods 
2.1 Pre-binding VN:GF to culture wells 
   To reflect more accurately the cellular environment in vivo we ‘pre-bound’ the VN:GF 
complexes to culture dishes [8, 27, 28]. We routinely adopt this approach because cells in 
vivo are likely to encounter growth factors bound to the ECM rather than in ‘solution-phase’ 
[29]. Thus, VN:GF complexes were precoated onto 48-well tissue culture plates (Nagle-Nunc, 
Denmark) and the lower membrane surface of 12-µm pore 12-well Transwells® (Costar, 
USA). Firstly, 150 µL of DMEM containing 162 ng VN (Promega, Australia), or 600 µL of 
DMEM containing 648 ng VN, was added to each well of a 48-well plate and lower chamber 
of a 12-well Transwell® plate, respectively. These were incubated for two hours at 37 ºC, 
after which the media containing unbound VN was removed by aspiration. Subsequently 125 
µL, or 500 µL of HEPES binding buffer (HBB) (0.1 M HEPES, 0.12 M NaCl, 5 mM KCl, 
1.2 mM MgSO4, 8 mM glucose, pH 7.6) containing IGF-I (54 ng) (Novozymes, Australia), 
IGFBP3 (162 ng) (Upstate Biotech, USA) and EGF (54 ng) (Novozymes), or IGF-I (216 ng), 
IGFBP3 (648 ng) and EGF (216 ng) was added to the 48-well plates, or 12-well Transwell®, 
respectively, and incubated for a further two hours at 37 ºC. The media containing the growth 
factor complexes was removed and the wells were washed with 500 µL, or 1 mL HBB, 
respectively. 
2.2 HA solution preparation  
   Human recombinant hyaluronic acid (rhHA) (954 kDa) (Novozymes A/S, Denmark) was 
dissolved in double-distilled water (10 mg/mL) for 2 hr at 37 ºC. This solution was filter-
sterilised (0.22 µm) (3 mg/mL) and stored at -20 ºC. The final concentration of HA was 
determined to be 3 mg/ml after filtration due to difficulties associated with HA’s viscosity. 
2.3 Migration assay  
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   The human skin keratinocyte (HaCaT) cell line (DKFZ, Germany)  and human foreskin 
fibroblast (HFF) cell line (ATCC, America) were routinely maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Invitrogen, Australia) supplemented with 5% foetal 
bovine serum (FBS) (HyClone, USA). All culture media were further supplemented with 0.1 
µL/mL gentamicin, 50 µL/mL streptomycin sulfate and 50 units/mL penicillin G (Invitrogen).  
Migration assays were performed as previously described with the following modifications [8, 
28]. HaCaT and HFF cells were starved and seeded into the upper chamber of pre-treated 12-
well Transwells® at a density of 1.5 x 105 cells in 400 µL serum-free medium (SFM). HA 
was added in 250 µL to the lower chamber with or without pre-bound VN:GF. Cells were 
thus exposed to 2, 6, 20, 60, 200, 600 and 2000 µg of HA in the presence or absence of 
VN:GF complexes in a final volume of 1 mL/well. The vessels were incubated for 10 hr at 37 
ºC, 5% CO2/95% air and cells that had not migrated through the microporous membrane to 
the lower chamber were gently removed using a flattened cotton bud. Cells located on the 
lower surface of the porous membrane (migrated) were fixed in 3.7% para-formaldehyde 
(Univar, Australia) and stained with 0.01% crystal violet (Sigma-Aldrich Pty Ltd, Australia) 
in phosphate buffered saline (PBS). The crystal violet stain was extracted in 10% acetic acid 
(BDH Laboratory Supplies, England) and the optical density (corresponding to the number of 
cells) was determined at 595 nm using a 96-well plate reader (Benchmark Plus, Bio-Rad, 
UK) [30].  
2.4. Proliferation assay  
HaCaT and HFF cells were starved and seeded into the 48-well plates at a density of 2.5 x 
104 cells in 375 µL SFM. Subsequently, various concentrations of HA in 125 µL were added 
to the wells. Wells were therefore exposed to 1, 3, 10, 30, 100, 300 and 1000 µg of HA in 
both the absence and presence of VN:GF complexes in a final volume of  500 µL/well. The 
vessels were then incubated for 48 hr at 37 0C, 5% CO2/95% air. Viable cells were 
quantitated with the CyQUANT® NF Proliferation Assay (Invitrogen) as per the 
manufacturer’s instructions. Fluorescence was determined at λex 485nm, λem 530 nm in black 
96-well plates (PerkinElmer, USA) using a POLARstar Optima Microplate Reader (BMG 
LABTECH GmbH, Germany).   
2.5. Statistical analysis of 2D cell culture studies  
   All experiments were performed in triplicate and each treatment was tested individually 
three times in each assay. One-way ANOVA with Tukey’s post hoc tests (all group 
comparisons) was applied to determine significance, determined as p < 0.05. 
 2.6. Primary cell isolation and culture  
   Keratinocytes and fibroblasts were isolated from three unrelated patients and cultured as 
described previously [31]. Ex vivo cultivated keratinocytes and fibroblasts were seeded onto 
DEDs as described previously [31].   
2.7. Assessment of the potential of VN:GF complexes and HA using DED-HSEs  
   Coincident with elevation to the air:liquid interface, replicate DED-HSEs were treated daily 
with topical application of 40 µL VN:GF complexes 1x (0.3 µg VN + 0.3 µg IGFBP3 + 0.1 
µg IGF + 0.1 µg EGF ), VN:GF complexes 3x (0.9 µg VN + 0.9 µg IGFBP3 + 0.3 µg IGF + 
0.3 µg EGF), HA (60 µg) (Novozymes, Denmark), HA+VN:GF complexes 1x, HA+VN:GF 
complexes 3x or serum-free medium (SFM) (negative control). After a further 3 and 7 days 
of culture at the air-liquid interface, the DED-HSEs were stained with 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyletetrazolium bromide (MTT) and fixed in 4% formalin 
(United Biosciences, Australia) and processed for histological or immunohistochemical 
analysis [31, 32]. The thicknesses of the proliferative cell layer and differentiated cell layer 
present in each newly formed epidermis was quantitated using Scion Image software (Scion 
Corp, USA).  
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2.8. Assessment of the effects of VN:GF complexes and HA on incorporation of fibroblasts 
into the DED  
   Fibroblasts were seeded onto the reticular face of each DED as described above to create 
the DED-HSE. Coincident with elevation to the air:liquid interface, individual DED-HSEs 
were treated with; 1) 20 µL of VN:GF complexes (0.015 µg/µL VN + 0.015 µg/µL IGFBP3 + 
0.005 µg/µL IGF + 0.005 µg/µL EGF ); 2) 20 µL of HA (1.5 µg/µL); 3) HA+VN:GF 
complexes (0.015 µg/µL VN + 0.015 µg/µL IGFBP3 + 0.005 µg/µL IGF + 0.005 µg/µL EGF 
+ 1.5 µg/µL HA); or 4) serum-free medium (SFM) (negative control). After 3 days culture at 
the air-liquid interface, the DED-HSEs were fixed in 4% formalin for histological analysis. 
The fibroblast population was quantitated using Scion Image software.  
2.9. Statistical analysis of the 3D DED-HSE studies  
   Duplicate DED-HSEs from three unrelated patients were tested individually with each 
treatment within each assay, unless otherwise indicated. One-way ANOVA with Tukey’s 
post hoc tests (all group comparisons) was applied to analyse the data. Statistically significant 
differences were accepted when p < 0.05.  
3. Results 
3.1. Effect of VN:GF and HA on HaCaT and HFF migration and proliferation 
   We investigated if the presence of HA would affect VN:GF complexes-induced migration 
and proliferation of HaCaT cells. As shown in Fig. 1a, HaCaT cell migration is unaffected by 
the presence of HA alone. Moreover, the effect of VN:GF complexes on HaCaT migration is 
not altered by the presence of HA. Furthermore, the HA treatment alone has little effect on 
the proliferation of HaCaT cells. Likewise, the presence of HA does not alter the effect of 
VN:GF complexes on HaCaT proliferation (Fig. 1b). 
   We further examined the effect of HA on the migration and proliferation of HFF. As shown 
in Fig. 1c, HA alone has little effect on the migration of HFF. Moreover, the effect of VN:GF 
complexes on HFF migration is not affected by HA. Furthermore, the highest concentration 
of HA (1000 µg/500 µL) significantly increased HFF proliferation, 433% ± 26% above 
control SFM (p <0 .01). Similarly, cell proliferation was stimulated two-fold by HA (> 600 
µg/mL) in the presence of VN:GF complexes (Fig. 1d). These data demonstrate HA 
significantly stimulates HFF proliferation and confers additional enhancement to VN:GF 
complex-stimulated proliferation, albeit only at the higher concentrations of HA tested.                                      
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3.2. Effect of VN:GF complexes and HA on the outgrowth of keratinocytes in DED-HSE 
model  
   We employed the 3D DED-HSE model to investigate the influence of VN:GF complexes 
and HA on keratinocyte outgrowth (Fig. 2a). No statistically meaningful differences were 
found between DED-HSEs treated with any of the different treatments (p > 0.05) (Fig. 2b). 
These results indicate that HA alone enhances keratinocyte outgrowth to a small extent and 
that the addition of HA does not alter the effect of VN:GF complexes. 
             
3.3. Effect of VN:GF complexes and HA on growth and differentiation of the epidermis in 
DED-HSE model  
   Immunohistochemistry was undertaken to detect the expression of specific markers on the 
surface of cells in the DED-HSE. Immunohistochemical analysis with a monoclonal antibody 
raised against the nuclear transcription factor p63 revealed the presence of undifferentiated 
proliferating cells. At day 3, intense immunoreactivity of p63 was detected in keratinocytes 
within the suprabasal and basal layers of the DED-HSEs treated with VN:GF complexes, HA 
or HA+VN:GF complexes. However, decreased immunoreactivity was detected in 
keratinocytes within the deeper basal layers of the DED-HSEs treated with VN:GF 1x and 
HA+VN:GF 3x complexes at day 7 (Fig 3, 4). Immunohistochemical analysis with a 
monoclonal antibody raised against keratins 1, 10, 11 (K1/10/11) revealed the presence of 
differentiated cells. Positive immunoreactivity of K1/10/11 was present in DED-HSE treated 
with VN:GF complexes, HA or HA+VN:GF complexes at both day 3 and day 7 (Fig 3, 4). 
Immunohistochemical analysis with a type IV collagen antibody revealed the presence of the 
basement membrane. Positive immunoreactivity of collagen IV was present in DED-HSE 
treated with VN:GF complexes, HA or HA+VN:GF complexes at both day 3 and day 7 (Fig 3, 
4). Immunohistochemical analysis with a keratin 14 (K14) antibody revealed the presence of 
basal cells. Intense immunoreactivity of K14 was detected DED-HSEs treated with 
HA+VN:GF 1x and VN:GF 3x complexes, but not HA+VN:GF 3x complexes at either day 3 
or day 7 (Fig 3, 4).  
   The epidermis partitions into two layers: a proliferative layer and a differentiated layer. The 
thickness of these two layers was quantitated (Fig. 3b and 4b) as a surrogate indicator of 
homeostasis. The thickness of the proliferative layer in DED-HSEs exposed to VN:GF 
complexes 1x, HA+VN:GF complexes 1x, HA, VN:GF complexes 3x and HA+VN:GF 
complexes 3x were significantly greater than control SFM. The thickness of the differentiated 
layers treated with VN:GF complexes 1x, HA+VN:GF complexes 1x, HA, VN:GF 
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complexes 3x and HA+VN:GF complexes 3x were also significantly thicker than the control 
SFM, with a depth of 29.23 ± 2.57 µm, 20.51 ± 1.32 µm, 12.56 ± 1.13 µm, 35.52 ± 0.13 µm 
and 27.78 ± 1.72 µm above, respectively, observed (p < 0.05) (Fig. 3b). These results suggest 
that VN:GF complexes, HA and HA+VN:GF complexes significantly enhance keratinocyte 
proliferation and differentiation in the ex vivo DED-HSE model.  
   Interestingly, the differences in the depth of the proliferative layers between DED-HSEs 
treated with VN:GF complexes, HA and HA+VN:GF complexes was lost with prolonged 
treatment  (i.e. 7 days) (Fig. 4b). However, the thicknesses of differentiated layers in DED-
HSEs treated with VN:GF complexes 1x, VN:GF complexes 3x and  HA+VN:GF complexes 
3x, remained statistically thicker than control-treated constructs (p < 0.05) (Fig. 4b). These 
results indicate that VN:GF complexes 1x, VN:GF complexes 3x and HA+VN:GF complexes 




3.4. Effect of VN:GF complexes and HA on incorporation of fibroblasts into the DEDs         
   We also examined the ex vivo colonisation of our DED-HSE models by donor-derived 
fibroblasts (Fig. 5a-d). The average number of fibroblasts successfully incorporated into 
DED-HSE models treated with VN:GF complexes, HA and HA+VN:GF complexes were 
6.42 ± 0.86, 7.67 ± 0.71 and 8.21 ± 0.89 per field of view, respectively. The average number 
of fibroblasts in control (SFM)-treated DED-HSEs was 5.54 ± 0.60 (Fig. 5e). These results 
indicate that VN:GF complexes alone, HA alone and HA+VN:GF complexes can enhance the 
incorporation of fibroblasts into DED-HSE, while HA does not alter the effect of VN:GF 
complexes on fibroblasts.  
 
    
4. Discussion 
   As growth factors play important roles during the wound healing process, extensive 
experimental investigations of their activities, both in vitro and in vivo, have been conducted. 
One family of growth factors thought to take part in the complex processes involved in skin 
growth and repair is the insulin-like growth factor (IGF) family, comprised of IGF-I and IGF-
II. These growth factors have various biological functions, including promotion of growth 
and development [33], regulation of cell proliferation and differentiation [34] and 
deoxyribonucleic acid (DNA) synthesis [35]. Primary keratinocytes normally express both 
insulin and IGF-I receptors and respond to either ligand during differentiation [36]. The role 
of epidermal factor (EGF)-stimulated cell motility in promoting wound healing has also been 
shown both in vitro in cell culture and in vivo in corneal and skin wounds [37]. Several other 
growth factors that are also involved in wound repair have been found to interact with 
components of the extracellular matrix (ECM) [38]. Following on from this, it is now thought 
that these growth factor:ECM interactions play a key role in most tissue growth and repair 
processes, including cell attachment, proliferation, migration, differentiation, cell survival 
and angiogenesis [7].   
   It has been found that vitronectin (VN), an ECM protein abundant in both the circulation 
and in tissues, increases epithelial outgrowth from skin organ explant cultures and supports 
the spreading of keratinocytes freshly isolated from guinea pigs [39]. VN also has been 
shown to induce enhanced motility of human keratinocytes in vitro [40] and provides an 
essential component of the temporary wound bed matrix [41]. Since the temporary wound 
bed matrix is rich in growth factors, the interaction between the ECM and growth factors is 
regarded as very important in wound healing [7]. Several growth factors involved in wound 
repair have been found to interact with components of the ECM [38]. For example, VN has 
been found to bind to IGF-family members [9, 27], epidermal growth factor (EGF) [42] and 
basis fibroblast growth factor (b-FGF) [43].  
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   Recent studies undertaken by our laboratory have investigated the functional effects of a 
substrate-bound complex composed of VN, IGF and EGF. Specifically, we have 
demonstrated that IGF-I associates with VN through IGFBPs [27]. Moreover, these trimeric 
complexes (IGF-I + IGFBP + VN) have been shown to enhance keratinocyte protein 
synthesis and migration [28]. Further, we have observed that the addition of EGF to the 
substrate-bound VN:IGF:IGFBP significantly increased the proliferation and migration of 
primary skin keratinocytes [8]. As to the precise mechanisms underlying the enhanced 
cellular responses to growth factors in the presence of VN, it has been proposed that “cross-
talk” occurs between growth factor receptors and αν integrins [29]. Growth factors are known 
to modulate the expression of integrin family members in tissue repair [44]. Indeed, recent 
studies from our own laboratory demonstrated that the novel VN:GF complexes enhance 
breast epithelial cellular migration via increased and sustained activation of the 
phosphatidylinositol 3-kinase/protein kinase B (PI3-K/AKT) signalling pathway through co-
activation of the IGF-1R and αν integrins [29]. In addition, it has been found that antibody 
inhibition of both the VN-binding αν integrins and the IGF-1R are critical for the enhanced 
keratinocyte migration observed in response to the VN:GF complexes in cell culture [9]. 
Moreover, to investigate the potential of the VN:GF complexes as a therapy for chronic 
wound healing, chronic wound fluid was added to replicate the in vitro environment of a 
chronic wound. We subsequently have demonstrated that the activity of the VN:GF 
complexes remains substantial, even in the presence of protease-rich chronic wound fluid 
collected from patients with chronic leg ulcers [9]. Furthermore, we have demonstrated that 
these VN:GF complexes also enhance the re-epithelialization of deep dermal partial-thickness 
burn injuries in a porcine model [9].  
   For our in vivo porcine study, VN:GF complexes were applied in water. For human 
applications water is a less than ideal excipient. Thus we investigated the potential of other 
approved formulations as a delivery vehicle for the VN:GF complexes. In particular, we 
examined the response of human keratinocytes and fibroblasts to topically delivered VN:GF 
complexes in the presence of hyaluronic acid (HA). HA is a high molecular weight 
polyanionic polysaccharide of the extracellular matrix, composed of repeated N-acetyl-D 
glucosamine and beta-glucoronic acid units [45]. HA is especially enriched in mammalian 
skin, in both dermis and epidermis [46]. Although the structure of HA is very simple, it has 
remarkable rheological, viscoelastic and hygroscopic properties that are critical to dermal 
tissue function. However, recently the role of HA in the mediation of physiological functions, 
such as morphogenesis, regeneration and wound healing [47] via its interaction with binding 
proteins and cell surface receptors has been recognised. It also has been reported that HA 
dynamically regulates cell signalling and behaviour [48]. Furthermore, interactions between 
HA and its cognate cell surface receptors, CD44 and hyaladherin (RHAMM), are thought to 
facilitate cell adhesion, cell motility, and cellular proliferation . It was for these reasons that 
we examined whether HA held potential as a carrier for the delivery of the VN:GF complexes 
to wounds. 
   Of interest to us, Kothapalli and Ramamurthi (2008) have reported that concurrent delivery 
of hyaluronan and IGF-I increased elastin regeneration by adult rat vascular cells [49]. In 
addition, a HA pack impregnated with IGF-I was found to enhance re-epithelialisation in a 
sheep wound model [50], and a wound dressing composed of a HA sponge containing EGF 
decreased the size of full-thickness skin defects and increased epithelisation in a rat wound 
model [51]. We therefore hypothesized that HA would have a facilitating role, and may 
perhaps even potentiate or maximize, the cellular responses to the VN:GF complexes. We 
tested this hypothesis using our system of pre-binding VN:GF complexes to culture vessels 
[52], exposing cells to these immobilised complexes and assaying the proliferation and 
migration of HaCaTs and HFFs in the presence and absence of HA.  
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   We observed that HA alone has little effect on the proliferation of HaCaTs. In addition, the 
presence of HA does not alter the effect of VN:GF complexes on HaCaT proliferation (Fig. 
1b). However, HA stimulated the proliferation of HFF fibroblasts (Fig. 1d), confirming the 
observations of Greco et al. (1998) [53]. Mohapatra et al. (1996) have reported that the 
progression of fibroblasts through the cell cycle is regulated by the interactions of HA with 
the cell surface receptor, RHAMM [54]. In particular, HA ligation of RHAMM maintains the 
level of Cdc2/cyc B1 complex kinase activity, permitting cells to progress through the G2/M 
phase of the cell cycle [53]. Our observation that VN:GF complexes enhanced the 
proliferation of HFF, and that this response is further enhanced by HA (Fig. 1d), raises the 
possibility of cross-talk between RHAMM and the IGF cell surface receptor (IGF-IR). Indeed, 
RHAMM has previously been associated with growth factor-regulated signalling, including 
signalling by PDGF [55]. 
   In addition to cell proliferation, cell migration is also critical to the re-epithelialisation of 
cutaneous wounds. We have previously reported that the migration of keratinocytes and 
fibroblasts is significantly enhanced in the presence of the VN:GF complexes [56]. Thus we 
assayed the migration of HaCaT and HFF cells to determine whether the presence of HA also 
affected VN:GF complexes-stimulated cell migration. We observed no significant difference 
in cell migration when HaCaTs and HFFs were exposed to a range of concentrations of HA 
alone (Fig. 1a, c). Furthermore, the addition of HA to VN:GF complexes did not further 
enhance the migration of HaCaTs and HFFs (Fig. 1a, c).  
   We also evaluated the effects of VN:GF complexes and HA using a 3D cell culture 
approach and primary cells derived from adult human skin [57, 58]. The 3D approach we 
employed, the DED – HSE model, exhibits similar morphology, structure and functional 
biochemistry to native human skin; hence, provides an ex vivo tool to investigate the effect of 
potential therapeutics [32]. Indeed, this 3D culture system allows keratinocytes to grow, 
differentiate and function as a living organ; with a stratified epidermis composed of a stratum 
basale, stratum spinosum, stratum granulosum and stratum corneum, as exists in vivo [32, 59, 
60]. This model therefore enables the migration, proliferation and differentiation of 
keratinocytes to be studied in a rigorously controlled system.  
   Experimental results from our DED-HSE studies indicate firstly that VN:GF complexes 
enhanced keratinocyte proliferation and differentiation and that this response is sustained and 
dose-dependent. The thickness of the proliferative and differentiating layers of the epidermis, 
whose formation involves keratinocyte migration, proliferation and differentiation, is 
significantly increased by application of VN:GF complexes (Fig. 3, 4). Secondly, these 
results demonstrate that HA alone is a significant stimulus of keratinocyte migration, 
proliferation and differentiation (Fig. 3). These findings corroborate previous reports, which 
suggest that HA stimulates keratinocyte migration, proliferation and differentiation through 
interactions with the cell surface HA receptors CD44 and hyaladherin RHAMM [61-63]. 
These 3D HSE-DED results are also consistent with previous clinical trials showing that skin 
lesions could be improved when HA is applied topically [64]. However, the data presented 
here is different from the 2-D cell culture results that we reported, which indicated that HA 
alone has little effect on the migration and proliferation of HaCaT cells. This may be 
explained by the difference between the 2-D and 3-D culture systems, as well as differences 
between the HaCaT cell line and keratinocytes derived from human skin. Thirdly, 
HA+VN:GF complexes were found to significantly enhance the development of both the 
proliferative and the differentiating layers of the DED-HSE model. The 
immunohistochemical analysis indicated that the addition of HA to the VN:GF complexes 
has a variable effect on the expression of K14. A stimulatory effect of HA in K14 immuno-
reactivity in the presence of the lower concentration of VN:GF complexes was observed, but 
not at the higher concentration of VN:GF complexes. Therefore, HA may well be enhancing 
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the delivery of lower concentrations of the VN: GF complexes in skin wound healing, given 
that the migration and proliferation of basal cells play key roles in re-epithelialisation [65] 
(Fig 3, 4).  
   Fibroblasts were also introduced and responses to VN:GF complexes and HA were assayed 
in our 3D DED-HSE model. Reproducing the experimental outcomes we observed in the 2D 
(monolayer) model we noted that greater numbers of fibroblasts were present in the DEDs 
treated with HA alone and HA+VN:GF complexes than we observed in our serum-free 
control samples (Fig. 5).  
   In summary, the results we report here indicate for the first time that HA can significantly 
enhance keratinocyte and fibroblast cellular responses. Although HA does not in the main 
enhance, nor indeed inhibit, the effect of VN:GF complexes on cellular responses of skin 
cells, the degradation products of HA,  such as the oligosaccharides and very low molecular 
weight HA, may enhance chronic wound healing in the in vivo chronic wound environment. 
In fact, low molecular weight HA has previously been shown to induce secretion of 
antimicrobial peptides such as β-defensin 2 [66], human beta defensin (HBD) 1, HBD2, 
HBD3, human cathelicidin (LL37), secretory leukocyte protease inhibitor (SLPI) and 
lactoferrin [67]. In addition, oligosaccharides of HA have been found to induce angiogenesis 
through CD44 and RHAMM-mediated signalling pathways [68]. In contrast, low molecular 
weight HA may also hinder chronic wound repair due to their reported roles in multiple pro-
inflammatory activities [69]. However, we believe that the widely documented positive 
effects of low molecular weight HA and its associated oligosaccharides are likely to outweigh 
any potential increase in inflammation. While our data does not indicate an enhancement of 
the cellular responses to VN:GF, the use of HA as a delivery vehicle for VN:GF in wound 
healing applications may confer other advantages, including the physicochemical properties 
of HA noted earlier, which confer it with an ability to sustain elevated pericellular 
concentrations of these species, thus potentially prolonging interactions with cell surface 
receptors and protecting them from degradation. Indeed, HA has previously been successfully 
used as a delivery vehicle for a range of dermal drugs, including diclofenac [11], ibuprofen 
[70], Clindamycin phosphate [71] and cyclosporine [72]. The beneficial effects of HA in 
these situations has been reported to include: enhancing both the partitioning of drugs into 
human skin and its retention and localization in the epidermis; and minimizing percutaneous 
absorption of drugs and assisting the transport of drugs to the epidermis [73]. HA has also 
been employed to deliver protein and peptide drugs such as insulin and recombinant human 
interleukin 11 (rhIL11) to enhance the absorption of the hormone or/and achieve a sustained 
release [74, 75]. Our future studies will therefore be focussed on determining the underlying 
mechanisms behind the coordinated regulation between VN:GF and HA, and exploring those 
parameters mentioned in the studies cited above. In addition we aim to investigate the 
chemical modification and crosslinking of HA monomers into hydrogel materials [76]. For 
example, temperature-sensitive HA hydrogels synthesized by photopolymerization of vinyl 
group modified HA in combination with acrylate group end-capped poly(ethylene glycol)-
poly(propylene glycol)-poly(ethylene glycol) tri-block copolymer resulted in a sustained 
release of recombinant human growth hormone [77]. In addition, an injectable HA-tyramine 
hydrogel system has been shown as a suitable injectable and biodegradable system for the 
delivery of therapeutic proteins [78]. Such modified or crosslinked HA hydrogels could 
protect the VN:GF proteins from thermal, pH and proteolytic changes in vivo, thus providing 
more effective and controlled delivery and release in vivo [79].  
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